Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PKLR | P30613 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2447653 | 0.86 | PKM (0.56) | CLK1CDK5CDK5R1CA12CA9 | |
| SCHEMBL19385392 | 0.79 | CLK1 (0.52) | CLK1CDK5CDK5R1CA12CA9 | |
| SCHEMBL15553635 | 0.79 | TNFSF11 (0.53) | CLK1CDK5CDK5R1CA12CA9 | |
| SCHEMBL3299198 | 0.79 | HSD17B10 (0.52) | CLK1CDK5CDK5R1CA12CA9 | |
| SCHEMBL981675 | 0.79 | NQO2 (0.49) | CLK1CDK5CDK5R1CA12CA9 | |
| SCHEMBL11731716 | 0.79 | PKM (0.52) | CA12CA9NQO2PKMPKLR | |
| SCHEMBL3298386 | 0.79 | LMNA (0.55) | CA12CA9NQO2PKMPKLR | |
| SCHEMBL29929188 | 0.79 | LMNA (0.55) | CA12CA9NQO2PKMPKLR | |
| SCHEMBL27929617 | 0.78 | NQO2 (0.61) | CA12CA9NQO2PKMPKLR | |
| SCHEMBL982452 | 0.78 | ELANE (0.65) | CLK1CDK5CDK5R1PKMPKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184567-B | Process for preparing 3-haloindole derivatives | 常州工程职业技术学院 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024140595-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118184567-A | Process for preparing 3-haloindole derivatives | 常州工程职业技术学院 | 2024-06-14 | — | — | CN | disclosed |
| EP-2915804-B1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-9988680-B2 | Non-natural nucleosides as theranostic agents | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988680-B2 | Non-natural nucleosides as theranostic agents | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2825546-B1 | NON-NATURAL NUCLEOSIDES AS THERANOSTIC AGENTS | UNIV CASE WESTERN RESERVE (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-2825546-B1 | NON-NATURAL NUCLEOSIDES AS THERANOSTIC AGENTS | UNIV CASE WESTERN RESERVE (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008058402-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-05-22 | — | — | WO | disclosed |
| EP-1842923-A1 | Methanesulfonylaminoindole derivatives and labeled oligonucleotide probes containing them. | Roche Diagnostics GmbH (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20070196852-A1 | Labeling reagent | ROCHE DIAGNOSTICS GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070196852-A1 | Labeling reagent | ROCHE DIAGNOSTICS GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070196852-A1 | Labeling reagent | ROCHE DIAGNOSTICS GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20060216736-A1 | Labeling reagent | ROCHE DIAGNOSTICS OPERTIONS, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1700922-A2 | Nitroindole derivatives and labeled oligonucleotide probes containing them | Roche Diagnostics GmbH (DE) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | CLK1 1181/4885CDK5 305/4885CDK5R1 291/4885 |
| US-20060216736-A1 | Labeling reagent | DUT, NUDT1, NT5C2 | CLK1 3043/4885CDK5 663/4885CDK5R1 808/4885 |
| US-20070196852-A1 | Labeling reagent | INMT, RNGTT, DUT | CLK1 3346/4885CDK5 495/4885CDK5R1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.